“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
Launches a new progression program and COVID-19 (K-NK-ID101)
Expands Kiadis K-NK generation to infectious diseases
Announces collaboration with five leading Dutch institutions: Viroclinics-DDL; Harbour BioMed Netherlands; Sanquin Bloedvoorziening; Erasmus Medical Center; and the University of Utrecht, providing an exclusive strength in studies and knowledge in virology and COVID-19
Grant filed with the U.S. government.
Amsterdam, Netherlands, August 17, 2020 – Kiadis Pharma NV (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinically prepared biopharmaceutical company that presents state-of-the-art cellular medicines for life-threatening diseases, announces a new curriculum, K-NK-ID101, which will focus on the progression of K-NK cells as a remedy for COVID-19. This new program marks the beginning of a broader application of Kiadis’ K-NK generation platform as a forward-looking remedy, not only for cancer, but also for infectious diseases.
In the K-NK-ID101 program, Kiadis began working with five leading Dutch establishments to examine other antiviral mechanisms of Kiadis’ K-NK mobile treatment platform against SARS-CoV-2, the virus that caused the COVID-19 pandemic. The collaboration will examine the biology of NK mobiles in patients with COVID-19, the elimination of SARS-CoV-2 virus viruses and inflamed mobiles with K-NK mobiles and synergies between monoclonal antibodies, vaccines and K-NK mobiles.
Natural killer mobiles (NK) are the first line of defense of the human immune formula opposed to tumor mobiles and infectious diseases. Mobile activity of K-NK has been shown to be opposed to cytomegalovirus (CMV) and BK virus in K-NK002 trials, and is opposed to CNS and fungal and pulmonary bacteria in K-NK003 assays.
COVID-19 breaks the immunity of NK cells and severe patients with COVID-19 lack functional NK cells. K-NK-ID101 cells have prospectively advanced antiviral activity, while avoiding unnecessary inflammation, and would possibly be suitable for solving this lack of functional NK cells. Because K-NK-ID101 cells can be manufactured on a giant scale and frozen, they can be manufactured without delay and manufactured globally for patients to have. In addition, the extensive antiviral activity of K-NK cells can also prospectively serve as a universal countermeasure to combat long-term viral pandemics; Kiadis will receive more information about the platform’s perspectives through studies conducted through these collaborations.
Robert Friesen, PhD, Chief Scientific Officer of Kiadis, said: “Our unique K-NK mobile generation platform is widely applicable in a variety of healing areas. Although our initial focus has been on blood cancers, we are now expanding our studies on infectious diseases and have established relationships with experts in the education and progression of antiviral drugs and COVID-19, in order to expand our K-NK mobile cures for the remedy. COVID-19. Significant evidence suggests that our K-NK-ID101 mobile cure would possibly be offering an exclusive and meaningful remedy for COVID-19. We look forward to running with this valuable organization to make a good contribution to combating this pandemic.
Arthur Lahr, Kiadis CEO, added: “We believe that K-NK cell-based drugs can simply be a vital component of the arsenal needed to combat this global pandemic and provide a forward-looking platform for universal pandemic preparedness. To help K-NK -ID101 Program, we have implemented it for U.S. government grants. In this global combat opposed to COVID-19. This program demonstrates the scope of the application of our K-NK platform and marks the start of a broader application of K-NK cells. as a prospective treatment, not only for cancer, but also for infectious diseases.
Kiadis collaborators come with leaders in SARS-CoV-2 studies from the Department of Virosciencia of the Erasmus Medical Center in Rotterdam and the Division of Infectious Diseases of the Faculty of Veterinary Medicine of the University of Utrecht. These two educational teams were the first to report on a monoclonal antibody that prevents the SARS-CoV-2 virus from infecting cultured cells (Nature Com.11 2215, 2020). Harbour BioMed Netherlands will bring the resistant anti-SARS-CoV-2 antibodies resulting from these studies to the Kiadis program. Viroclinics Xplore, which features models of viral disease, dosage and animal models for SARS-CoV-2, completes the program. Viroclinics-DDL is a world-renowned viral contract study organization and has contributed particularly to viral studies for past pandemics, adding SARS1 and pandemic influenza. Sanquin will carry out the characterization of the presence and serve NK cells in patients with recovered COVID-19, its exclusive group of donor curtains in the Dutch population.
About Kiadis K-NK Cell Therapies The Kiadis K-NK Mobile Cure in Immuno-Oncology is composed of haploidic and mobile curator products from ready-to-use donors for the treatment of liquid and forged tumors such as adjuvants and autonomous therapies. Kiadis is also looking to use its K-NK mobile cure platform for infectious disease remedy, the first prospective application being the COVID-19 remedy.
The company’s PM21 particle generation allows for ex vivo expansion and activation of K-NK’s anticancer cytotoxic mobiles that support high-dose infusions. Kiadis’ patented K-NK mobile platform is based on NK mobile phones from exclusive universal donors. Kiadis’ out-of-the-box K-NK platform can make the NK mobile treatment product temporarily and inexpensively available to a giant patient population in a wide variety of potentially indications.
Kiadis clinically develops K-NK003 for the remedy of relapsed/refractory acute myeloid leukemia. The company also develops K-NK002, which is administered as an additional immunotherapeutic in addition to GCSH and supplies functional, mature and resistant NK mobiles from a member of the haploidénetic family. In addition, the company has preclinical systems that compare the NK mobile cure for the treatment of counterfeit tumors.
About NK and K-NK mobiles in COVID-19 The clinical justification for the examination of the infusion of herbal killer mobiles (NK) to COVID-19 disease is supported by the literature. The vast majority of patients with COVID-19 have lymphocytopenia or lymphocyte shortage, a type of white blood mobile that helps protect the body from infections. NK mobile phones are lymphocytes and the severity of COVID-19 disease correlates with relief in the number of NK mobiles, depletion of NK mobiles and the absence of safe and mature NK mobile phenotypes. The strength of NK mobiles to combat various other viral infections, such as CMV, BKV, HBV and HCV, has been well described, with a lasting change in the profile of NK mobiles towards those more mature and resistant phenotypes in cured patients.
Kiaidis studies aim to examine the homes of Kiadis K-NK cells and their ability to combat SARS-CoV-2 and evolve as pre-exposure prophylaxis and post-exposure preventive treatment in high-risk patients and fitness care painters. K-NK cells multiple facets of antiviral immunity. In immunocompromised transplant patients, K-NK cells showed significant relief in the life-threatening reactivation of CMV and BKV infection. K-NK cell paints in synergy with antibodies, immunoglobulins and vaccines.
K-NK cells are studied for their antiviral properties, the protection profile and the scalability of production and will potentially be widely implemented as a global countermeasure against COVID-19 and long-term pandemic threats.
Kiadis Contacts
Kiadis: Maryann Cimino, Senior Manager, Corporate Affairs Tel: (617) 710-7305 [email protected]
LifeSpring LifeSciences Communication: Leon Melens (Amsterdam) Tel: ‘31538 [email protected] Optimal Strategic Communications: Mary Clark, Supriya Mathur Tel:’ 44203950 9144 [email protected]
Dutch translation / Nederlandse vertaling
Kiadis Pharma N.V. (Euronext Amsterdam in Brussel: KDS) is a Nederlands beursgenoteerd biotechbedrijf dat nieuwe geneesmiddelen ontwikkelt tegen ernstige ziekten. Het maakt daarbij gebruik van Natural Killer-cellen (NK-cellen), grote witte bloedlichamen die de eerste verdedigingslinie in het menselijk afweersysteem vormen tegen kankercellen in infecties. Kiadis is unieke Kiadis-NK-cellen (K-NK-cellen) een nieuw onderzoeksprogramma gestart genaamd K-NK-ID01, voor de behandeling van COVID-19, de ziekte die wordt veroorzaakt door het SARS-CoV-2 virus. Kiadis breidt hiermee de toepassing van K-NK-cellen uit naar behandeling van kanker through infectieziekten.
Kiadis gaat samen Erasmus MC, Universiteit Utrecht, Sanquin Bloedvoorziening en de Nederlandse bedrijven Viroclinics en Harbour BioMed Netherlands, onderzoek doen naar de werking van de Kiadis ‘K-NK-cellen tegen het corona virus dat COVID-19 verozaakt. Daarbij zullen de partijen onder andere onderzoeken hoe de K-NK-cellen kunnen worden gecombineerd al eerder door Erasmus MC, Harbour BioMed at Universiteit Utrecht-ontdekte antilichamen tegen het coronavirus.
Patianten met ernstige COVID-19 hebben een gebrek aan goed werkende NK-cellen. En eerdere Kiadis onderzoeksprogramma’s is krachtige werking van Kiadis ‘K-NK-cellen aangetoond tegen varied viral, schimmel- in bacteriele infectiouss in het bloed, longen en het central zenuwstelsel van ernstig zieke pati-nelf serve as-kunnen K-NK mogelijk ook het gebrek aan goed werkende NK-cellen bij COVID-19 pati-nten herstellen.
K-NK-ID101 cellen kunnen in de toekomst op grote schaal worden geproduceerd en onmiddellijk voor pati-nen beschikbaar worden gemaakt. De brede werking van NK-cellen tegen virusen maakt K-NK-ID101-cellen daarmee mogelijk een universeel middel in de strijd tegen wereldwijde pandemieon.
Robert Friesen, Ph.D. scientific director van Kiadis, zegt:
“Ons unieke K-NK-cel-technologyplatform is of breed toepasbaar voor meerdere ziekten. We had all the various systems onderzoeks voor de behandeling van kanker, in breiden 11 activiteiten nu uit naar behandeling van infectieziekten. Once K-NK-ID101-celtherapiekten. kan mogelijk tot een unieke behandeling van COVID-19 leiden. We kijken er naar uit om samen met sterke netwerk van gerenommeerde Nederlandse onderzoeksgroepen een een effectieve behandeling te ontwikkelen in the strijd tegen het coronavirus dataktie of COVIDo-19za.
Arthur Lahr, CEO of Kiadis, vult aan: “K-NK-cellen kunnen in de toekomst op grote schaal geproduceerd worden en onmiddellijk beschikbaar komen bij behandeling van viral Infections. Geneesmiddelen op base van K-NK-cellen kunnen daarmee molangrijk een wapen vormen tegen deze en toekomstige pandemieon. Webben voor said K-NK-ID101-programma subventie aangevraagd bij of Amerikaanse overheid. Dit programma toont het brede potentieel van ons K-NK-platform, niet alleen als mogelijkankerijn te behandeling van infectieziekten. »
University specialist in SARS-CoV-2-onderzoek van de afdeling Viroscience van het Erasmus Medisch Centrum in Rotterdam and of afdeling Infectieziekten van de Veterinaire Faculteit van Universiteit Utrecht nemen deel aan denwerking. Deze academische groepen ontdekten als eerste monoklonale antilichamen die infectie met het SARS-CoV-2-virus tegengaan (Nature Com. (2020) 11: 2215). Harbour BioMed Netherlands zal deze SARS-CoV-2-antilichamen in de samenwerking inbrengen. Viroclinic is a contract gerenommeerde conderzoeksorganisatie en heeft baanbrekend onderzoek gedaan bij eerdere pandemieon, waaronder SRAS and pandemische griep. Viroclinics is eigenaar van gepatenteerde viral ziektemodellen, testen at diermodellen voor SARS-CoV-2. Sanquin Bloedvoorziening zal de aanwezigheid en functie van NK-cellen bij COVID-19 pati-nten en kaart brengen, gebruik makend van donormateriaal van herstelde COVID-19 pati-nten.
It says persbericht vormt een vertaling van het gepubliceerde Engelstalige persbericht. Bij eventualuele verschillen es de tekst van het Engelstalige persbericht altijd bepalend.
About Kiadis Founded in 1997, Kiadis is building a fully incorporated biopharmaceutical company committed to the advancement of state-of-the-art cell-based drugs for patients with life-threatening diseases. Headquartered in Amsterdam, the Netherlands, and with activities in the United States, Kiadis is reinventing medicine by leveraging the herbal forces of humanity and our collective immune formula for downloading cells for life.
Kiadis has been indexed on the Euronext Amsterdam and Euronext Brussels regulated market since 2 July 2015, with the symbol KDS. Learn more about www.kiadis.com.
Forward-looking statements Certain statements, ideals and revisions contained in this press release are forward-looking and reflect Kiadis’ existing expectations and projections or, if applicable, Kiadis executives related to long-term occasions. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties, and assumptions that may cause actual effects, performance, achievements, or occasions to differ materially from those expressed, expected, or implied through forward-looking statements. These risks, uncertainties and assumptions may adversely be the outcome and monetary effects of the plans and occasions described herein. A multitude of factors, including but not limited to demand adjustments, regulation, festival, and technology, can cause real occasions, performances, accomplishments, or effects to differ materially from any planned or implied development. Future statements contained in this press release relating to trends or activities beyond them deserve not to be considered as a representation that these trends or activities will continue in the long term. Accordingly, Kiadis expressly waives any legal duty or commitment to factor in any updates or revisions to any forward-looking statements in this press release as a result of any repositioning in expectations or projections, or any repositioning on occasions, conditions, assumptions or cases on which such forward-looking statements are based. Neither Kiadis, its advisers or representatives, nor any of its subsidiaries, officers or workers ensure that the assumptions underlying such forward-looking statements are error-free and do not accept any duty for the long-term accuracy of forward-looking statements. in this press release or the actual occurrence of planned or implied developments. You deserve not to place undue reliance on forward-looking statements, which relate only to the date of this press release.